A single-arm, prospective clinical study on the efficacy and safety of anti-mycobacteria in the treatment of periductal mastitis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049591

Enrollment

Unknown

Registered

2021-08-05

Start date

2013-01-01

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

periductal mastitis

Interventions

Case group:anti-mycobacteria treatment

Eligibility

Sex/Gender

Female

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Meet the pathological diagnostic criteria for periductal mastitis; 2) Non- puerperal female patients aged 15-75; 3) No serious organic disease or serious infection of other systems; 4) patients with informed consent;

Exclusion criteria

Exclusion criteria: 1) Women during lactation and pregnancy; 2) People with allergies or allergies to isoniazid, rifampicin, ethambutol; 3) Complicated with other breast infectious diseases or breast cancer at the same time; 4) Patients with other serious system diseases; 5) The patient does not agree to participate in the clinical trial.

Design outcomes

Primary

Measure	Time frame
clinical cure rate;	—

Secondary

Measure	Time frame
Clinical remission rate;Recurrence rate;	—

Countries

China

Contacts

Public ContactYu Zhigang

The Second Hospital of Shandong University

yzg@medmail.com.cn+86 13864182636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026